Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China
Joint Authors
Xu, Chenjia
Guo, Ruru
Huang, Dandan
Ji, Jian
Liu, Wei
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-08-10
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Background.
The aim of this study was to compare the daily costs and cost effectiveness of fixed combination glaucoma drugs in China.
Methods.
This study included the following fixed combination drugs: brinzolamide 1% and timolol 0.5% (Azarga; Alcon, Inc., Fort Worth, TX, USA), travoprost 0.004% and timolol 0.5% (DuoTrav; Alcon, Inc.), bimatoprost 0.03% and timolol 0.5% (Ganfort; Allergan, Inc., Dublin, Ireland), and latanoprost 0.005% and timolol 0.5% (Xalacom; Pfizer, Inc., New York, NY, USA).
Five bottles of each drug were measured.
The mean actual volume, mean actual number of drops, volume per drop, daily cost, yearly cost, and per mmHg reduction cost for each drug were calculated.
Results.
The volumes per drop ranged from 32.61 ± 2.90 μl (DuoTrav) to 24.38 ± 0.23 μl (Ganfort).
The number of usage days per bottle varied from 36 days (DuoTrav) to 61 days (Ganfort).
Azarga had the lowest daily cost ($0.23) and yearly cost ($84.72), while DuoTrav had the highest daily cost ($0.79) and yearly cost ($287.02).
Azarga costed $2.17–$3.30 per mmHg intraocular pressure reduction, which was lower than the other three drugs.
For the prostaglandin and ß-adrenergic blocker FCs, Ganfort had the lowest daily cost ($0.35) and per mmHg reduction cost (from $3.40 to $4.04).
Conclusions.
The daily costs of these drugs were significantly different, with Azarga having the lowest daily cost and best cost effectiveness.
For the prostaglandin and β-adrenergic blocker fixed combinations, Ganfort was the most economical choice with its lower daily cost and per mmHg reduction cost.
The results of this study could provide drug selection guidance from an economic perspective, but various factors should be considered when making a decision.
American Psychological Association (APA)
Xu, Chenjia& Guo, Ruru& Huang, Dandan& Ji, Jian& Liu, Wei. 2020. Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. Journal of Ophthalmology،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1189324
Modern Language Association (MLA)
Xu, Chenjia…[et al.]. Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. Journal of Ophthalmology No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1189324
American Medical Association (AMA)
Xu, Chenjia& Guo, Ruru& Huang, Dandan& Ji, Jian& Liu, Wei. Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China. Journal of Ophthalmology. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1189324
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1189324